NATICK, Massachusetts, January 5 /PRNewswire/ -- Boston Scientific Corporation today announced that it has completed enrollment in its MAPS(TM) clinical trial, which is studying the coiling of intracranial aneurysms. This prospective, randomized trial commenced enrollment in 2007 and has reached its goal of 630 patients, enrolled at 47 hospitals in 11 countries. Principal investigators for the trial are Anil Gholkar, O.B.E., M.B.B.S., Clay Johnston, M.D., Ph.D., and Cameron McDougall, M.D.

The MAPS trial compares clinical outcomes in patients treated with either bare-platinum GDC(R) Detachable Coils or Matrix2(R) Detachable Coils, which are covered with a bio-polymer. The primary endpoint is Target Aneurysm Recurrence (TAR) at one year, a composite clinical endpoint of target aneurysm rupture or re-rupture, re-treatment or neurologic death. Secondary angiographic endpoints will be compared to the primary clinical outcomes over several years to evaluate the long-term predictive value of 12-month angiography.

The MAPS trial has significant potential to enhance our understanding of the products we use to treat intracranial aneurysms as well as our methods for assessing outcomes, said Dr. Gholkar. By conducting rigorous measurement, monitoring and adjudication of clinical outcomes over multiple years, the MAPS trial will establish a critical baseline from which to judge existing treatments as well as future endovascular technologies.

Aquilla Turk, D.O., is the Chairman of the MAPS Steering Committee and enrolled the final patient in the trial. With enrollment completed, our focus now turns to data monitoring, completion of follow up and preparation for primary endpoint publication in 2011, said Dr. Turk. The Steering Committee is grateful to all the trial investigators who have worked so diligently to reach this milestone.

This important trial is the latest example of Boston Scientific's 24 years of collaboration and leadership in the field of neurointervention and lays the groundwork for continued advances in the minimally invasive treatment of brain aneurysms, said Mark Paul, President of Boston Scientific's Neurovascular business. We appreciate the participation of the 124 physicians and 63 research coordinators, whose efforts led to the successful completion of enrollment.

For more information on the MAPS Trial visit:

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

CONTACT: Geraldine Varoqui Boston Scientific Public Relations International +49-170-782-85-58

SOURCE: Boston Scientific Corporation

CONTACT: Geraldine Varoqui, Boston Scientific, Public RelationsInternational, +49-170-782-85-58,